News
Moderna to conduct new mRNA trials in Taiwan
Courtesy of ICRT
The senior vice president of Moderna says the pharmaceutical company believes Taiwan is a "crucial site for clinical trials" necessary for refining its mRNA technology.
Patrick Bergstedt says it will include Taiwan as a site for its multicentre trials. The statement comes as Bergstedt makes his first visit to Taiwan since Moderna launched a subsidiary here in September.
Bergstedt says the company is hoping to tap into Taiwan's world-famous healthcare system, medical research capacity, and innovations in the biotech sector to provide people with more disease prevention and treatment options. The Moderna senior vice president says the company is also seeking to collaborate with healthcare experts here in Taiwan to help the country meet challenges in healthcare.
Moderna will launch clinical trials of 15 nascent or neglected transmissive diseases next year, with an emphasis on respiratory diseases. Moderna Taiwan General Manager Joyce Lee says preliminary results from those studies are expected to become available in March.
